About 5,000 lawsuits are pending, including some from patients crippled by tiny particles of metallic debris
The DePuy orthopedic division of Johnson & Johnson, citing declining sales, began phasing out both models of the device — formally known as an articular surface replacement device, which DePuy marketed under the name ASR — in November 2009 and formally recalled them in August 2010 amid reports in databases of orthopedic patients abroad showing they were failing prematurely at high rates.
But in a confidential letter, the F.D.A. told Johnson & Johnson in August 2009 that company studies and clinical data submitted to gain approval in the United States to sell the model available overseas were inadequate to determine the implant’s safety and effectiveness, according to a summary of the letter reviewed by The New York Times.
In the article Iowa Women’s Health Study, much of the piece takes many things that are...
The first goal of the Paul Amendment is to reign in FDA overreach in regulating dietary...
To reasonable people it makes a whole lot of sense that the act of pumping tons...
In a medical science first, researchers turned skin cells from heart failure patients into heart muscle...
